AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Biophharmaceutical company reports cash position, net cash expenditures for Q3.
2004 DEC 1 - (NewsRx.com & NewsRx.net) -- Transgene (TRGNY) announced cash position and net cash expenditures for the third quarter and the 9 months ended September 30, 2004 (unaudited figures, USGAAP).
Net cash expenditures amounted to EUR 4.8 million (US$6.0 million) and EUR 14.9 million (US$18.5 million) for the third quarter and the first 9 months of 2004, respectively. The net cash expenditures for the third quarter and the first 9 months of 2003 amounted to EUR 4.1 million (US$5.1 million) and EUR 13.8 million (US$17.1 million), respectively. The increase in net cash expenditures in the first 9 months of 2004 reflects a refund of research tax credit of EUR 0.2 million (US$0.2 million) in 2004 compared to EUR 0.8 million (US$1.0 million) in 2003 and a decrease of interest income due to lower cash held, cash outflows being unchanged.
Cash and cash equivalents ...
- Transgene: Cash Position and Net Cash Expenditures as of September 30, 2004.
- Press release article from: PR Newswire November 3, 2004 700+ words
...announced cash position and net cash expenditures for the third quarter and...unaudited figures, USGAAP). Net cash expenditures amounted to euro 4.8 million...2004, respectively. The net cash expenditures for the third quarter and...
- Transgene: Net Cash Expenditures and Cash Position as of September 30, 2006.
- Press release article from: PR Newswire October 11, 2006 700+ words
...announces its cash position and net cash expenditures for the nine months ending...first nine months of 2006: - Net cash expenditures amounted to EUR 15.9 million...in line with the expected net cash expenditures of approximately EUR 22 million...
- Transgene: Net cash expenditures and cash position as of 30 Sep 2006.
- News wire article from: Chemical Business Newsbase October 11, 2006 700+ words
...announces its cash position and net cash expenditures for the nine months ended...first nine months of 2006: Net cash expenditures amounted to EUR 15.9 M...in line with the expected net cash expenditures of about EUR 22 M for 2006...
- Transgene: Cash Position and Net Cash Expenditures as of March 31, 2005.
- Press release article from: PR Newswire April 13, 2005 700+ words
...announced its cash position and net cash expenditures at and for the three months...unaudited figures, US GAAP). Net cash expenditures amounted to euro 4.6 million...the first quarter of 2005. Net cash expenditures for the first quarter of...
- Transgene : Cash Position and Net Cash Expenditures as of September 30, 2005.
- Press release article from: PR Newswire October 19, 2005 700+ words
...announces its cash position and net cash expenditures for the nine months ending...increase in Europe. The net cash expenditures, excluding the effect of...third quarter of 2004. The net cash expenditures for the first nine months...
- Transgene: Cash Position and Net Cash Expenditures as of March 31, 2006.
- Press release article from: PR Newswire April 12, 2006 700+ words
...announces its cash position and net cash expenditures for the 3 months ending March...at March 31, 2006. The net cash expenditures amounted to EUR 5.3 million...of 2005, in line with the net cash expenditures to the order of EUR 21 million...
- Transgene: Net Cash Expenditures and Cash Position as of March 31, 2007.
- Press release article from: PR Newswire April 16, 2007 700+ words
...FR0005175080) announces its cash position and net cash expenditures for the three months ending March 31, 2007 (unaudited...31, 2007. For the first three months of 2007, net cash expenditures amounted to EUR 6.7 million compared to EUR 5...
- Zonagen Focuses Resources On Vasomax and Vasofem; Reduces Cash Expenditures.
- Press release article from: Business Wire September 13, 1999 700+ words
...will focus its resources on its lead product candidates -- Vasomax(R) and Vasofem(TM). This action will reduce cash expenditures by concentrating the Company's talents and assets on programs that have the greatest potential to impact shareholder...
- Zonagen Announces Plan to Review Strategic Alternatives and Reduce Cash...
- Press release article from: Business Wire July 27, 2000 700+ words
...delays associated with the Company's lead product VASOMAX(R). At the same time, the Board has elected to reduce cash expenditures and conserve resources as part of the redeployment strategy. Accordingly, Zonagen will pare headcount to the minimum...
- Loudeye Announces Significant Progress in Restructuring; Actions Have Resulted...
- Press release article from: PR Newswire May 6, 2003 700+ words
...efforts. In the last 45 days, the company has achieved these key milestones: -- More than $7 million reduction in annual cash expenditures; and -- More than $5 million reduction in real estate obligations. In March 2003 Loudeye implemented a restructuring...
Source: HighBeam Research, Biophharmaceutical company reports cash position, net cash...